Cargando…

Testosterone concentrations and prescription patterns of 1% testosterone gel in transgender and gender diverse individuals

BACKGROUND: Masculinising hormone therapy with testosterone is used to align an individual’s physical characteristics with their gender identity. Standard testosterone doses and formulations recommended for hypogonadal cisgender men are typically administered, although there are currently limited da...

Descripción completa

Detalles Bibliográficos
Autores principales: Nolan, Brendan J., Zwickl, Sav, Wong, Alex F. Q., Locke, Peter, Simpson, Satu, Li, Ling, Zajac, Jeffrey D., Cheung, Ada S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918760/
https://www.ncbi.nlm.nih.gov/pubmed/35296035
http://dx.doi.org/10.1177/20420188221083512
_version_ 1784668800704053248
author Nolan, Brendan J.
Zwickl, Sav
Wong, Alex F. Q.
Locke, Peter
Simpson, Satu
Li, Ling
Zajac, Jeffrey D.
Cheung, Ada S.
author_facet Nolan, Brendan J.
Zwickl, Sav
Wong, Alex F. Q.
Locke, Peter
Simpson, Satu
Li, Ling
Zajac, Jeffrey D.
Cheung, Ada S.
author_sort Nolan, Brendan J.
collection PubMed
description BACKGROUND: Masculinising hormone therapy with testosterone is used to align an individual’s physical characteristics with their gender identity. Standard testosterone doses and formulations recommended for hypogonadal cisgender men are typically administered, although there are currently limited data evaluating the use of 1% testosterone gel in gender-affirming hormone therapy regimens. OBJECTIVES: The objective of the study was to assess the prescription patterns and serum total testosterone concentrations achieved with 1% testosterone gel in trans and gender diverse individuals. MATERIALS AND METHODS: A retrospective cross-sectional analysis was undertaken of trans individuals at a primary and secondary care clinic in Melbourne, Australia. Sixty-seven individuals treated with 1% testosterone gel were included. Primary outcomes were testosterone dose and serum total testosterone concentration achieved. RESULTS: Median age was 25 (22–30) years and median duration of testosterone therapy was 12 (7–40) months. Thirty-five (52%) individuals had a nonbinary gender identity. Initial median testosterone dose was 25 mg (12.5–31.3) daily. Fifty-two (78%) individuals commenced doses <50 mg daily, the recommended starting dose for hypogonadal cisgender men. Median total testosterone concentration achieved was 11.9 nmol/l (7.3–18.6). Polycythaemia (haematocrit >0.5) was documented in eight of 138 (6%) laboratory results in six individuals. DISCUSSION AND CONCLUSIONS: One percent testosterone gel achieves serum total testosterone concentrations in the cisgender male reference range. A high proportion of individuals had a nonbinary gender identity and most individuals commenced a lower dose than that typically administered to hypogonadal cisgender men, potentially related to slow or ‘partial’ masculinisation goals.
format Online
Article
Text
id pubmed-8918760
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-89187602022-03-15 Testosterone concentrations and prescription patterns of 1% testosterone gel in transgender and gender diverse individuals Nolan, Brendan J. Zwickl, Sav Wong, Alex F. Q. Locke, Peter Simpson, Satu Li, Ling Zajac, Jeffrey D. Cheung, Ada S. Ther Adv Endocrinol Metab Gender-Affirming Endocrine Care and Health Outcomes in Transgender and Gender Diverse Individuals BACKGROUND: Masculinising hormone therapy with testosterone is used to align an individual’s physical characteristics with their gender identity. Standard testosterone doses and formulations recommended for hypogonadal cisgender men are typically administered, although there are currently limited data evaluating the use of 1% testosterone gel in gender-affirming hormone therapy regimens. OBJECTIVES: The objective of the study was to assess the prescription patterns and serum total testosterone concentrations achieved with 1% testosterone gel in trans and gender diverse individuals. MATERIALS AND METHODS: A retrospective cross-sectional analysis was undertaken of trans individuals at a primary and secondary care clinic in Melbourne, Australia. Sixty-seven individuals treated with 1% testosterone gel were included. Primary outcomes were testosterone dose and serum total testosterone concentration achieved. RESULTS: Median age was 25 (22–30) years and median duration of testosterone therapy was 12 (7–40) months. Thirty-five (52%) individuals had a nonbinary gender identity. Initial median testosterone dose was 25 mg (12.5–31.3) daily. Fifty-two (78%) individuals commenced doses <50 mg daily, the recommended starting dose for hypogonadal cisgender men. Median total testosterone concentration achieved was 11.9 nmol/l (7.3–18.6). Polycythaemia (haematocrit >0.5) was documented in eight of 138 (6%) laboratory results in six individuals. DISCUSSION AND CONCLUSIONS: One percent testosterone gel achieves serum total testosterone concentrations in the cisgender male reference range. A high proportion of individuals had a nonbinary gender identity and most individuals commenced a lower dose than that typically administered to hypogonadal cisgender men, potentially related to slow or ‘partial’ masculinisation goals. SAGE Publications 2022-03-11 /pmc/articles/PMC8918760/ /pubmed/35296035 http://dx.doi.org/10.1177/20420188221083512 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Gender-Affirming Endocrine Care and Health Outcomes in Transgender and Gender Diverse Individuals
Nolan, Brendan J.
Zwickl, Sav
Wong, Alex F. Q.
Locke, Peter
Simpson, Satu
Li, Ling
Zajac, Jeffrey D.
Cheung, Ada S.
Testosterone concentrations and prescription patterns of 1% testosterone gel in transgender and gender diverse individuals
title Testosterone concentrations and prescription patterns of 1% testosterone gel in transgender and gender diverse individuals
title_full Testosterone concentrations and prescription patterns of 1% testosterone gel in transgender and gender diverse individuals
title_fullStr Testosterone concentrations and prescription patterns of 1% testosterone gel in transgender and gender diverse individuals
title_full_unstemmed Testosterone concentrations and prescription patterns of 1% testosterone gel in transgender and gender diverse individuals
title_short Testosterone concentrations and prescription patterns of 1% testosterone gel in transgender and gender diverse individuals
title_sort testosterone concentrations and prescription patterns of 1% testosterone gel in transgender and gender diverse individuals
topic Gender-Affirming Endocrine Care and Health Outcomes in Transgender and Gender Diverse Individuals
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918760/
https://www.ncbi.nlm.nih.gov/pubmed/35296035
http://dx.doi.org/10.1177/20420188221083512
work_keys_str_mv AT nolanbrendanj testosteroneconcentrationsandprescriptionpatternsof1testosteronegelintransgenderandgenderdiverseindividuals
AT zwicklsav testosteroneconcentrationsandprescriptionpatternsof1testosteronegelintransgenderandgenderdiverseindividuals
AT wongalexfq testosteroneconcentrationsandprescriptionpatternsof1testosteronegelintransgenderandgenderdiverseindividuals
AT lockepeter testosteroneconcentrationsandprescriptionpatternsof1testosteronegelintransgenderandgenderdiverseindividuals
AT simpsonsatu testosteroneconcentrationsandprescriptionpatternsof1testosteronegelintransgenderandgenderdiverseindividuals
AT liling testosteroneconcentrationsandprescriptionpatternsof1testosteronegelintransgenderandgenderdiverseindividuals
AT zajacjeffreyd testosteroneconcentrationsandprescriptionpatternsof1testosteronegelintransgenderandgenderdiverseindividuals
AT cheungadas testosteroneconcentrationsandprescriptionpatternsof1testosteronegelintransgenderandgenderdiverseindividuals